Immunic Q1 FY26 net loss widens to $32.6 million

IMMUNIC INC

IMMUNIC INC

IMUX

0.00
  • Immunic posted a net loss of USD 32.6 million for first-quarter 2026, widening from a loss of USD 25.5 million a year earlier.
  • Loss per share narrowed to USD 1.08 from USD 2.51, while R&D expense climbed 19.07% to USD 25.6 million and G&A costs rose 43.4% to USD 7.6 million.
  • Cash and cash equivalents totaled USD 186.6 million at March 31, 2026; the company expects to fund operations into late 2027.
  • Immunic reiterated top-line data from twin Phase 3 ENSURE trials of vidofludimus calcium in relapsing multiple sclerosis is expected by end-2026, with a planned U.S. NDA submission in mid-2027 and a targeted potential approval date in 2028.
  • Appointed Michael A. Panzara as chief medical officer, raised USD 200 million upfront in a private placement with potential for up to an additional USD 200 million, and said it plans to initiate a Phase 3 program in primary progressive multiple sclerosis later this year.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immunic Inc. published the original content used to generate this news brief via EQS News, a service of EQS Group AG (Ref. ID: corporate_2326394_en), on May 13, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.